Table 3.
mRNA expression levels of MMP-2, MMP-9, PR-A, and PR-B in ovarian endometriosis and endometrial tissues obtained from women with and without endometriosis
| Different object | Endometriotic lesions (ectopic) | Eutopic endometrium (endometriosis group) | Endometrium (control group) | P value |
|---|---|---|---|---|
| MMP-2 | 0.16 (0.05, 1.45) | 0.15 (0.05, 0.87) | 0.12 (0.06, 0.29) | 0.512 |
| MMP-9 | 0.02E-1 (0.03E-2, .021)*Δ | 0.03E-2 (0.01E-2, 0.06E-2) | 0.03E-2 (0.09E-3, 0.07E-2) | 0.005 |
| PR-A | 27.20 (9.99, 206.33) | 76.98 (9.00, 268.03) | 67.05 (16.60, 231.78) | 0.643 |
| PR-B | 0.04E-2 (0.03E-3, .01E-1)*Δ | 0.03E-1 (0.01E-1, 0.07E-1) | 0.04E-1 (0.01E-1, 0.09E-1) | 0.001 |
| Ln (PR-A/PR-B) | 11.79 ± 4.82 | 10.28 ± 4.64 | 9.81 ± 2.93 | 0.305 |
Data are expressed as mean ± standard deviation or median (inter-quartile range) when appropriate. ANOVA was performed on the natural-log-transformed values when appropriate. MMP; Matrix metalloproteinase, PR; Progesterone receptor, *; P<0.05 versus endometriotic lesions compared to the controls, and Δ; P<0.05 versus endometriotic lesions compared to the eutopic endometrium.